- Previous Close
487.60 - Open
488.80 - Bid 505.50 x --
- Ask 508.00 x --
- Day's Range
488.80 - 508.00 - 52 Week Range
281.20 - 554.00 - Volume
24,106 - Avg. Volume
46,525 - Market Cap (intraday)
8.84B - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
64.96 - EPS (TTM)
7.82 - Earnings Date Feb 5, 2025
- Forward Dividend & Yield 4.00 (0.79%)
- Ex-Dividend Date Oct 11, 2024
- 1y Target Est
545.00
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops as well as develops XcytoMatic 30 cell counter. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
chemometec.comRecent News: CHEMM.CO
View MorePerformance Overview: CHEMM.CO
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHEMM.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHEMM.CO
View MoreValuation Measures
Market Cap
8.84B
Enterprise Value
8.55B
Trailing P/E
64.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.67
Price/Book (mrq)
15.64
Enterprise Value/Revenue
20.96
Enterprise Value/EBITDA
44.07
Financial Highlights
Profitability and Income Statement
Profit Margin
33.41%
Return on Assets (ttm)
15.83%
Return on Equity (ttm)
24.82%
Revenue (ttm)
407.87M
Net Income Avi to Common (ttm)
136.28M
Diluted EPS (ttm)
7.82
Balance Sheet and Cash Flow
Total Cash (mrq)
296.15M
Total Debt/Equity (mrq)
0.74%
Levered Free Cash Flow (ttm)
41.28M